Evaluation of the Survival of HER2-Positive Breast Cancer Patients Receiving Herceptin Compared With Those Who Did Not Receive It


HER2 Positive
Breast Cancer

How to Cite

Akhavan, A., Binesh, F., Hoseini-Dezki, S. S., & Mortazavizadeh, S. M. R. (2018). Evaluation of the Survival of HER2-Positive Breast Cancer Patients Receiving Herceptin Compared With Those Who Did Not Receive It. Internal Medicine and Medical Investigation Journal, 3(2), 63-68. https://doi.org/10.24200/imminv.v2i4.122


Introduction: Breast cancer is the most common type of cancer that affects women. Human epidermal growth factor receptor 2 (HER2) is a gene that plays a significant role in the development of breast cancer. The aim of this study was to compare the survival of HER2-positive breast cancer patients who received Herceptin with those who did not receive it in Yazd, Iran.

Materials and Methods: Our study was an analytical cross-sectional study. Sampling was done on all patients with HER2-positive invasive ductal carcinoma (HER2 positive) who were referred to Shahid Sadoughi Hospital or Shahid Ramezanzadeh Hospital from 2003 to 2014. The data were collected using a questionnaire, which included questions on age, type of tumor, tumor grade, recurrence history, tumor size, number of lymph nodes, and whethr Hercepin was received or not received. Data were then entered into SPSS version 18 and analyzed by statistical tests.

Results: The mean age of the patients was 50.78 ± 10.75 years. The mean survival time was 61.61 ± 2.93 months, and the mean recurrence time was 104.104 ± 41.3 months. The results also showed that there was no statistically significant difference between the 2 groups, despite the higher mean survival time and less recurrence time in patients receiving Herceptin compared with those who did not receive Herceptin (P>.05).

Conclusions: According to the results of this study, the efficacy of Herceptin as a neoadjuvant treatment in the survival of HER2-positive breast cancer patients has not been established.


- WHO (October 2010). "Cancer". World Health Organization. Retrieved 5 January 2011.

- Benson JR, Jatoi I. The global breast cancer burden. Future Oncol. 2012;8:697–702.

- Coughlin S, Ekwueme D. Breast cancer as a global health concern. Cancer Epidemiol. 2009;33:315–8.

-Maximiano S, Magalhaes P, Guerreiro MP, Morgado M. Trastuzumab in the Treatment of Breast Cancer. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2016;30(2):75-86.

- Nitta H, Kelly BD, Allred C, Jewell S, Banks P, Dennis E, et al. The assessment of HER2 status in breast cancer: the past, the present, and the future. Pathology international. 2016 Jun;66(6):313-24. PubMed PMID: 27061008.

- Garnock-Jones KP, Keating GM, Scott LJ. Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. BioDrugs. 2010;24:207–9.

- McKeage K, Lyseng-Williamson KA. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. Pharmacoeconomics. 2008;26:699–719.

- Patani N, Mokbel K. Herceptin and breast cancer: an overview for surgeons. Surg Oncol. 2010;19:11–21.

- Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. Breast. 2013;22:S152–5.

- Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–83.

-Khodabakhshi R, Gohari MR, Moghadamifard Z. Disease-Free Survival of Breast Cancer Patients and Identification of Related Factors. Razi Journal of Medical Sciences.2011;18(89):27-39.

-Gohari MR, Mahmoudi M, Kazem M, Pasha E, Khodabakhshi R. Recurrence in breast cancer analysis with frailty model. Saudi Med J; 2006. 27(8):1187-93.

-Vahdaninia M, Montazeri A. Breast cancer in Iran: a survival analysis. Asian Pac J Cancer Prev; 2004. 5(2):223-25.

- Mousavi SM, Mohagheghi MA, Mousavi Jerrahi A, Nahvijou A, Seddighi Z. Outcome of breast cancer in Iran: a study of Tehran center registry data. Asian Pac J Cancer Prev; 2008.9(2):275-78.

- Sajadi A, Gregory H, Bajdik CH, Bashash M, Ghorbani A, Nouraie M, et al. Comparison of breast cancer survival in two populations: Ardabil, Iran and British Columbia, Canada. BMC Cancer; 2009. 9: 381-86.

- Heydari ST, Mehrabani D, Tabei SZ, Azarpira N, Vakili MA. Survival of breast cancer in southern Iran. IJCP; 2009. 1: 51-54.

- Akbari ME, Khayamzadeh M, Khoshnevis SJ, Nafisi N, Akbari A. Five and ten years survival in breast cancer patients mastectomies vs. breast conserving surgeries personal experience. IJBC;2008. 1(2): 53-56.

- Ian Smith, Marion Procter, Richard D Gelber, Sébastien Guillaume, Andrea Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch,et all. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007; 369: 29–36.

- Romond EH, Suman VJ, Jeong J-H, et al: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. 2012 San Antonio Breast Cancer Symposium. Abstract S5-5. Presented December 7, 2012.

- Karam I, Hamilton S, Nichol A, Woods A, Speers C, Kennecke H. (2013). Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras. Radiation Oncology, 8 (1), 12.

-Koizumi M, Yoshimoto M, Kasumi F, Iwase T. An open cohort study of bone metastasis incidence following surgery in breast cancer patients. BMC Cancer; 2010. 10:381-85.

-Alexieva FJ, Van putten WLJ, Blankenstein A, Blonk vander J, Klijn JGM. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Cancer; 1988. 4:758–68.

-Horita K, Yamaguchi A, Hirose K, Ishida M, Noriki S, Imamura Y, et al. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer. Eur J Histochem; 2001. 45(1):73-84.

-Wolberg WH, Street WN, Mangasarian OL. Importance of nuclear morphology in breast cancer prognosis; 1999. 5:3542–48.

- Heitz F, Rochon J, Harter P, Lueck HJ, Fisseler-Eckhoff A, Barinoff J, et al. Cerebral metastases in metastatic breast cancer: diseasespecific risk factors and survival. Ann Ancol. 2011. 22(7):1571-81.

- Louis P, Pertschuk DO, Joseph G, Feldman DPH, Karen RN, Anne C. et al. lmmuonocytochermical detection of progesterone receptor in breast cancer with monoclonal antibody. Relation to biochemical assay, disease-free survival and clinical endocrine response. Cancer; 2006. 62(2):342-49.

- Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Ancol. 2008. 19:1242–48.

-Mehranfar S, Zeinali S, Hosseini R, Mohammadian M, Akbarzadeh A, Feizi AH. History of Leukemia: Diagnosis and Treatment from Beginning to Now. Galen Medical Journal. 2017 Apr 1;6(1):12-22

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.